erlotinib hydrochloride has been researched along with piperazine in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (piperazine) | Trials (piperazine) | Recent Studies (post-2010) (piperazine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,139 | 8 | 521 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatnagar, PK; Chaira, T; Cliffe, I; Das, B; Dastidar, SG; Diwan, M; Gupta, P; Kumar, A; Malik, R; Malik, S; Nithya, D; Pamidiboina, V; Ray, A; Senthil, V; Tandon, R; Venkataramanan, R | 1 |
1 other study(ies) available for erlotinib hydrochloride and piperazine
| Article | Year |
|---|---|
RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Drug Stability; ErbB Receptors; Erlotinib Hydrochloride; Female; HT29 Cells; Humans; Male; Membrane Potential, Mitochondrial; Mice; Microsomes, Liver; Mutation; Phosphorylation; Piperazine; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |